140 related articles for article (PubMed ID: 26896751)
1. Mechanisms of BRAFi-induced hyperproliferative cutaneous conditions.
Ali M; Anforth R; Senetiner F; Carlos G; Fernandez-Penas P
Exp Dermatol; 2016 May; 25(5):394-5. PubMed ID: 26896751
[No Abstract] [Full Text] [Related]
2. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
Sibaud V; Lamant L; Maisongrosse V; Delord JP
Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.
Anforth R; Menzies A; Byth K; Carlos G; Chou S; Sharma R; Scolyer RA; Kefford R; Long GV; Fernandez-Peñas P
J Am Acad Dermatol; 2015 May; 72(5):809-15.e1. PubMed ID: 25748298
[TBL] [Abstract][Full Text] [Related]
4. Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors.
Vigarios E; Lamant L; Delord JP; Fricain JC; Chevreau C; Barrés B; Gomez-Roca C; Boulanger M; Sibaud V
Br J Dermatol; 2015 Jun; 172(6):1680-1682. PubMed ID: 25495246
[No Abstract] [Full Text] [Related]
5. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
6. Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma.
Viros A; Hayward R; Martin M; Yashar S; Yu CC; Sanchez-Laorden B; Zambon A; Niculescu-Duvaz D; Springer C; Lo RS; Marais R
J Invest Dermatol; 2013 Jan; 133(1):274-6. PubMed ID: 22895366
[No Abstract] [Full Text] [Related]
7. BRAFi-associated panniculitis - an emerging side effect with a variable histological picture: report of two cases and review of the literature.
Ferreira J; Toda-Brito H; Moura MC; Sachse MF; Costa-Rosa J
J Cutan Pathol; 2017 Mar; 44(3):307-309. PubMed ID: 27976808
[No Abstract] [Full Text] [Related]
8. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.
Anforth R; Tembe V; Blumetti T; Fernandez-Peñas P
Pigment Cell Melanoma Res; 2012 Sep; 25(5):569-72. PubMed ID: 22726224
[TBL] [Abstract][Full Text] [Related]
10. Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity.
Adelmann CH; Ching G; Du L; Saporito RC; Bansal V; Pence LJ; Liang R; Lee W; Tsai KY
Oncotarget; 2016 May; 7(21):30453-60. PubMed ID: 27028853
[TBL] [Abstract][Full Text] [Related]
11. Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors.
Erfan G; Puig S; Carrera C; Arance A; Gaba L; Victoria I; Garcia-Herrera A; Alos L; Malvehy J
Acta Derm Venereol; 2017 Feb; 97(2):258-260. PubMed ID: 27353949
[No Abstract] [Full Text] [Related]
12. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
Capovilla M
Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
[TBL] [Abstract][Full Text] [Related]
13. Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy.
Satzger I; Degen A; Asper H; Kapp A; Hauschild A; Gutzmer R
J Clin Oncol; 2013 May; 31(13):e220-2. PubMed ID: 23530102
[No Abstract] [Full Text] [Related]
14. Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma.
Cassius C; Pages C; Roux J; Lhote R; Lavocat R; Réa D; Bagot M; Mourah S; Battistella M; Lebbé C; Dumaz N
J Invest Dermatol; 2016 Jun; 136(6):1302-1305. PubMed ID: 26854489
[No Abstract] [Full Text] [Related]
15. Cutaneous effects of BRAF inhibitor therapy: a case series.
Mattei PL; Alora-Palli MB; Kraft S; Lawrence DP; Flaherty KT; Kimball AB
Ann Oncol; 2013 Feb; 24(2):530-537. PubMed ID: 23035153
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
[TBL] [Abstract][Full Text] [Related]
17. [BRAF: the pathologist's favorite oncogene].
Sabourin JC
Ann Pathol; 2013 Dec; 33(6):373-4. PubMed ID: 24331718
[No Abstract] [Full Text] [Related]
18. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors.
Anforth R; Blumetti TC; Clements A; Kefford R; Long GV; Fernandez-Peñas P
Br J Dermatol; 2013 Dec; 169(6):1310-3. PubMed ID: 23870055
[TBL] [Abstract][Full Text] [Related]
19. Clinical resolution of vemurafenib-induced squamous cell carcinoma with topical 5-fluorouracil.
Sinha R; Larkin J; Fearfield L
Br J Dermatol; 2015 Apr; 172(4):1135-6. PubMed ID: 25234953
[No Abstract] [Full Text] [Related]
20. Don't miss the base - keratoacanthoma-type squamous cell carcinoma with perineural invasion during BRAF inhibitor therapy for melanoma.
Schüürmann M; Pönitzsch I; Simon JC; Ziemer M
J Dtsch Dermatol Ges; 2015 Dec; 13(12):1279-81. PubMed ID: 26612802
[No Abstract] [Full Text] [Related]
[Next] [New Search]
